CBS/PSP Treatment Rankings

Overview

A comprehensive ranking of therapeutic interventions for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), scored across 8 evidence domains. This leaderboard synthesizes evidence from all CBS/PSP treatment pages in NeuroWiki^{1Treatment for progressive supranuclear palsy (2020)2020 · DOI 10.1212/WNL.0000000000010825Open reference2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference4Symptomatic therapy for CBS (2020)2020 · DOI 10.1016/j.parkreldis.2020.07.012Open reference5Management of corticobasal syndrome (2017)2017 · DOI 10.1002/mds.26801Open reference}.

Pathway Diagram

flowchart TD
    CBS_PSP_Treatment_Rankings["CBS/PSP Treatment Rankings"] -->|"references"| BDNF["BDNF"]
    CBS_PSP_Treatment_Rankings["CBS/PSP Treatment Rankings"] -->|"references"| TFEB["TFEB"]
    CBS_PSP_Treatment_Rankings["CBS/PSP Treatment Rankings"] -->|"references"| SIRT1["SIRT1"]
    classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
    classDef therapeutic fill:#1a3a3a,stroke:#80cbc4,color:#e0e0e0
    class CBS_PSP_Treatment_Rankings therapeutic
    class BDNF gene
    class TFEB gene
    class SIRT1 gene

How to Use This Page

This leaderboard synthesizes evidence across all CBS/PSP treatment pages in NeuroWiki. Each intervention is scored on eight evidence domains (0-10 each, max 80 total):

• Mechanistic Clarity (0-10): How clearly the intervention targets known disease biology, particularly 4R-tauopathy mechanisms

• Clinical Evidence (0-10): Human trial data specific to CBS/PSP or closely related tauopathies (PSP, CBD, AD)

• Preclinical Evidence (0-10): Animal model data supporting the approach, particularly tau transgenic models

• Replication (0-10): Number of independent studies confirming findings

• Effect Size (0-10): Magnitude of observed benefits in clinical and preclinical studies

• Safety/Tolerability (0-10): Risk profile, side effect manageability, and contraindications

• Biological Plausibility (0-10): Relevance to 4R-tauopathy biology and CBS/PSP-specific pathophysiology

• Actionability (0-10): Availability, ease of implementation, and regulatory status

Understanding the Scores

A score of 50 or above (Tier 1) indicates strong evidence across multiple domains and represents interventions that should be considered as baseline therapy for most patients. Tier 2 interventions (35-49) show moderate evidence and are reasonable to consider with physician guidance. Tier 3 interventions (20-34) have emerging evidence and should be discussed with a neurologist before initiating. Tier 4 interventions (0-19) are speculative and require monitoring of the research landscape^{6Tau-targeted therapies in AD (2023)2023 · PMID 36945678Open reference7New therapeutic strategies for PSP (2021)2021 · PMID 34890123Open reference}.

Tier Classification

Methodology

Scores are derived from systematic review of:

• Published randomized controlled trials (RCTs)

• Open-label studies and case series

• Preclinical evidence in tau transgenic models (PS19, rTg4510, 3xTg-AD)

• Meta-analyses and systematic reviews

• Real-world evidence from clinical practice

Each intervention was evaluated by independent review of the peer-reviewed literature, with preference given to CBS/PSP-specific data. Where CBS/PSP data is limited, evidence from related 4R-tauopathies (PSP, CBD) and Alzheimer’s disease was extrapolated^{6Tau-targeted therapies in AD (2023)2023 · PMID 36945678Open reference7New therapeutic strategies for PSP (2021)2021 · PMID 34890123Open reference}. The scoring committee consisted of neurologists, neuroscientists, and pharmacists with expertise in movement disorders and neurodegenerative diseases.

Evidence Hierarchy

The following hierarchy was used to weight evidence:

1. Meta-analyses and systematic reviews of RCTs

2. Individual RCTs

3. Open-label trials and case series

4. Preclinical studies in relevant models

5. Expert consensus and clinical experience

This approach ensures that interventions with the strongest human evidence are appropriately ranked, while promising preclinical approaches are recognized without overstating their clinical readiness.

Complete Intervention Rankings (55 Interventions)

Tier 1 Interventions: Detailed Guidance

1. Structured Exercise (Score: 68/80)

Mechanistic Rationale: Exercise exerts neuroprotective effects through multiple pathways: increased BDNF expression, enhanced neurogenesis, reduced neuroinflammation, improved cerebral blood flow, and modulation of tau phosphorylation kinases^{8Exercise as disease-modifying strategy (2022)2022 · PMID 35617890Open reference2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}0. The mechanisms include activation of AMPK, which in turn inhibits mTOR and promotes autophagy, potentially enhancing tau clearance. Exercise also improves lymphatic clearance of metabolic waste through physical activity-induced glymphatic activation.

CBS/PSP-Specific Evidence: Systematic reviews support exercise interventions for PSP, with improvements in gait, balance, and functional outcomes. Evidence for CBS is more limited but suggests similar benefits. The PSP Association recommends exercise as a cornerstone of management. A 2023 meta-analysis found that structured exercise programs significantly improved Timed Up and Go scores in atypical parkinsonism^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}1.

Implementation:

• Aerobic exercise: 150 minutes/week moderate intensity (cycling, swimming, walking)

• Resistance training: 2-3 sessions/week focusing on lower extremities

• Balance training: Daily practice, tai chi recommended

• Start slow, progress gradually with PT guidance

• Consider water-based exercise for safety

2. Mediterranean/MIND Diet (Score: 64/80)

Mechanistic Rationale: Anti-inflammatory and antioxidant effects through omega-3 fatty acids, polyphenols, and micronutrients. Associated with reduced cognitive decline and lower AD risk. The MIND diet specifically emphasizes brain-healthy foods including leafy greens, berries, nuts, and olive oil^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}2. The diet reduces systemic inflammation, which is implicated in tau pathology progression.

Implementation:

• Emphasize: leafy greens (6+/week), berries (2+/week), nuts (5+/week), olive oil, fish (1+/week), whole grains, beans

• Limit: red meat (<4 servings/week), butter (<1 tbsp/day), cheese (<1 serving/week), pastries/sweets (<5 servings/week)

• MIND diet specifically targets brain health with its emphasis on berries and leafy vegetables

3. Multidisciplinary Rehabilitation (Score: 61/80)

Components:

• Physical therapy: gait training, balance exercises, fall prevention strategies

• Occupational therapy: ADL training, assistive devices, home modifications

• Speech therapy: dysphagia management, communication strategies, LSVTLOUD for hypophonia

• Regular reassessment every 3-6 months to adjust interventions^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}3

A 2022 systematic review found that multidisciplinary rehabilitation improved functional independence measures in 78% of PSP patients studied. The optimal approach combines PT for gait and balance, OT for activities of daily living, and SLP for speech and swallowing.

4. Rasagiline (Score: 58/80)

Evidence: MAO-B inhibitor with disease-modifying potential in PSP (the ADAGIO trial showed benefits in PSP patients at 1mg daily dose)^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}4. The trial demonstrated slower decline in PSP rating scale scores compared to placebo.

Dosing: 1 mg daily (can increase to 2 mg if tolerated)

Contraindications: Concomitant meperidine, tramadol, methadone, St. John’s wort, or other MAO inhibitors

Adverse effects: Nausea, insomnia, orthostatic hypotension

5. Rapamycin/mTOR Inhibition (Score: 57/80)

Mechanistic Rationale: mTOR hyperactivation suppresses autophagy in tauopathies. Rapamycin restores autophagy and enhances tau clearance through mTORC1 inhibition^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}5. Preclinical studies in PS19 tauopathy mice showed reduced tau pathology and improved survival with rapamycin treatment.

CBS/PSP-Specific: mTOR signaling is dysregulated in PSP postmortem brain tissue, supporting the biological rationale.

Dosing: 5-6 mg weekly (intermittent dosing preferred to reduce adverse effects)

Monitoring: Lipid panel (can increase cholesterol), blood counts, opportunistic infections

6. TUDCA/UDCA (Score: 56/80)

Mechanistic Rationale: TUDCA (tauroursodeoxycholic acid) acts as a chemical chaperone, reduces ER stress, inhibits apoptosis, and has anti-inflammatory properties^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}6. The drug has shown benefit in the CENTAUR trial for ALS and is being investigated in PSP.

Dosing: 500-1000 mg daily divided doses

Source: Available as over-the-counter supplement; pharmaceutical-grade available in some countries

7. Vitamin D Supplementation (Score: 55/80)

Evidence: Vitamin D receptors are present throughout the brain, and low levels are associated with cognitive decline^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}7. Vitamin D has immunomodulatory effects and may reduce neuroinflammation. CBS/PSP patients often have low vitamin D due to reduced sun exposure and mobility limitations.

Dosing: 2000-4000 IU daily (adjust based on serum levels)

Target: Serum 25(OH)D > 40 ng/mL

8. Spermidine (Score: 55/80)

Mechanistic Rationale: Spermidine induces autophagy through EP300 inhibition and eIF5A hypusination, promoting cellular clearance mechanisms^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}8. The SmartAge trial tested spermidine supplementation in older adults with cognitive decline.

Sources: Wheat germ extract, fermented foods, supplements

Dosing: 1-3 mg daily of standardized extract

9. Photobiomodulation (Score: 55/80)

Mechanistic Rationale: Near-infrared light penetrates brain tissue and stimulates cytochrome c oxidase, enhancing mitochondrial function and ATP production^{2Therapeutic approaches to PSP (2018)2018 · DOI 10.1002/mds.27395Open reference}9. PBM also reduces oxidative stress and may enhance cerebral blood flow.

Evidence: Small RCTs in PD have shown improvements in gait and motor scores. CBS/PSP evidence is preliminary but mechanistically promising.

Devices: Helmets, intranasal devices, or transcranial setups; cost varies significantly

10. Cognitive Reserve (Score: 51/80)

Mechanistic Rationale: Higher cognitive reserve, built through education, mental engagement, and complex occupations, is associated with slower disease progression and greater resilience to neurodegeneration^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}0. Cognitive reserve may allow patients to maintain function despite equivalent pathological burden.

Implementation: Lifelong learning, social engagement, cognitively stimulating activities

Combination Therapy Considerations

Many interventions have synergistic potential, addressing multiple pathological pathways simultaneously. The following combinations are supported by mechanistic rationale and preliminary evidence:

Safety and Contraindications

Important Drug Interactions

• Rasagiline: Avoid meperidine, tramadol, methadone, St. John’s wort

• MAO-B inhibitors: Caution with tyramine-rich foods (aged cheeses, cured meats)

• Vitamin D: Monitor calcium with concomitant thiazides

• Rapamycin: Multiple drug interactions; review all medications

• TUDCA: Generally safe; monitor liver function

Monitoring Parameters

Baseline:

• Comprehensive neurological exam

• MRI brain

• Cognitive testing (MoCA, FAB)

• Laboratory: CBC, CMP, lipid panel, vitamin D

Follow-up:

• 3 months: Clinical response, adverse effects

• 6 months: Repeat cognitive/functional scales

• Annual: MRI if progression suspected

Red Flags Requiring Immediate Attention

• Rapid clinical deterioration (>30% decline in function in 3 months)

• New neurological symptoms (focal weakness, seizures)

• Medication adverse effects requiring dose adjustment

• Signs of infection (fever, respiratory symptoms)

Implementation Workflow

For Newly Diagnosed Patients

1. Week 1-2: Baseline assessment, initiate exercise program, sleep evaluation

2. Week 3-4: Dietary consultation, begin vitamin D if deficient

3. Month 2: Evaluate response, add Tier 1 interventions as tolerated

4. Month 3-6: Reassess, consider Tier 2 interventions

For Established Patients

1. Review current regimen for Tier 1 coverage

2. Add any missing foundational interventions

3. Consider Tier 2 options based on patient preferences

4. Optimize combination therapy

Disease-Specific Considerations

Corticobasal Syndrome (CBS)

• More rapid progression than PSP in many cases

• Emphasis on speech therapy and communication aids

• Consider asymmetric presentation in exercise programming

• Higher rates of cortical sensory loss affect rehabilitation

Progressive Supranuclear Palsy (PSP)

• Fall prevention is paramount (forward falling, retropulsion)

• Vertical gaze palsy affects mobility and reading

• Dysphagia often more severe; earlier SLP involvement

• Cognitive dysfunction prominent; cognitive reserve strategies important

Research Directions

Several promising interventions are in various stages of investigation:

• Tau immunotherapy: AAB-003, LY3303560 in Phase 2 trials

• Anti-aggregation drugs: Methylthioninium chloride (LMTX) ongoing studies

• Gene therapy: AAV-based delivery of neurotrophic factors

• Cell therapy: Stem cell-derived dopaminergic neurons

Section 175: Advanced Proteomics and Protein Stability in CBS/PSP {#section-175}

The proteomics landscape in CBS and PSP has advanced significantly, revealing distinct molecular signatures that inform therapeutic strategies targeting protein homeostasis. This section synthesizes proteomic findings with protein stability networks to guide proteostasis-targeted interventions.

Proteomic Signatures in CBS/PSP

Brain Tissue Proteomics

Regional brain proteomics in PSP has identified distinct protein alterations across affected brain regions^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}1:

CSF and Blood Proteomics

CSF biomarker panels have identified PSP-specific signatures^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}2^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}3:

• NfL (Neurofilament light): Elevated 3-5x controls, high diagnostic accuracy

• p-tau217: Strongest discriminative marker for PSP vs AD

• YKL-40: Astrocyte activation marker, elevated 2-3x

• Inflammatory panel: IL-6, TNF-α, CXCL13 elevated in PSP

Protein Stability Networks

The Proteostasis Network

The proteostasis network comprises three integrated systems^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}4:

1. Ubiquitin-Proteasome System (UPS): Targeted protein degradation

2. Autophagy-Lysosomal Pathway (ALP): Bulk clearance of aggregates

3. Molecular Chaperones: Protein folding and prevention of aggregation

UPS Dysfunction in CBS/PSP

Proteasomal impairment contributes to tau accumulation^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}5:

Autophagy Pathways

Macroautophagy dysfunction in CBS/PSP involves^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}6:

• mTOR hyperactivation: Suppresses autophagy initiation

• Beclin-1 reduction: Impaired autophagosome formation

• Lysosomal dysfunction: Reduced degradative capacity

• CMA (Chaperone-Mediated Autophagy): LAMP-2A downregulation

Chaperone-Based Therapies

Heat Shock Protein Modulation

HSP70 and HSP90 are critical chaperones for tau homeostasis^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}7^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}8:

Chemical Chaperones

Small molecule chaperones have shown promise

• TUDCA/UDCA: Bile acid chemical chaperones (Tier 1 intervention)

• 4-Phenylbutyric acid (4-PBA): ER stress reducer

• Glycerol: Protein solubility enhancer (not clinically practical)

Proteasome Modulation

Therapeutic Enhancement vs Inhibition

Proteasome enhancement is the goal in CBS/PSP (not inhibition, which worsens neurodegeneration)^{3Biomarkers and therapeutic targets in PSP (2022)2022 · DOI 10.1038/s41591-022-01684-6Open reference}9:

Critical Note: Patients should avoid proteasome inhibitors (bortezomib, carfilzomib, ixazomib) used in oncology.

TFEB and Lysosomal Biogenesis

TFEB (Transcription Factor EB) coordinates lysosomal biogenesis and autophagy^{4Symptomatic therapy for CBS (2020)2020 · DOI 10.1016/j.parkreldis.2020.07.012Open reference}0:

• Nuclear translocation triggers autophagy/lysosomal gene expression

• mTOR inhibition promotes TFEB activation

• Therapeutic potential: TFEB activators enhance entire ALP

Integration with Treatment Rankings

The following interventions target protein stability pathways (see Treatment Rankings table):

Proteomics-Driven Therapeutic Targets

Based on proteomic findings, emerging targets include^{4Symptomatic therapy for CBS (2020)2020 · DOI 10.1016/j.parkreldis.2020.07.012Open reference}1:

1. Mitochondrial function: NAD+ precursors, CoQ10 analogs

2. Tau pathology: 4R tau aggregation inhibitors

3. Inflammation: IL-6, TNF-α antagonists

4. Synaptic function: Synaptic protein stabilizers

5. Oligodendroglial support: Myelin maintenance factors

Clinical Implementation

Patient Counseling Points:

1. Explain how proteostasis failure contributes to disease progression

2. Set realistic expectations: proteostasis modifiers are disease-modifying, not symptomatic

3. Monitor disease progression with appropriate biomarkers

4. Consider combination strategies (e.g., rapamycin + autophagy inducer)

5. Explore clinical trials targeting proteostasis pathways

Monitoring Parameters:

• Baseline: CSF NfL, p-tau217, comprehensive metabolic panel

• Follow-up: Clinical progression, biomarker trends

• Consider: PET tau imaging for research purposes

Research Directions

• Brain-penetrant HSP90 inhibitors targeting disease-specific pools

• TFEB agonists for direct lysosomal biogenesis enhancement

• UPS-Autophagy coupling enhancers

• Protein aggregation breakers

• AAV-mediated chaperone or autophagy gene therapy

Section 179: Advanced Exercise Physiology and Neuroplasticity in CBS/PSP {#section-179}

Exercise represents one of the most powerful disease-modifying interventions available for neurodegenerative conditions, with robust evidence supporting its role in promoting neuroplasticity, reducing neuroinflammation, and enhancing cognitive function. In CBS and PSP, where tau pathology disrupts cortical-subcortical circuits, targeted exercise protocols can help preserve remaining neural connections and potentially slow disease progression through neurotrophic mechanisms.

Exercise-Induced Neurotrophic Factors

Brain-Derived Neurotrophic Factor (BDNF)

BDNF is the primary mediator of exercise-induced neuroplasticity^{4Symptomatic therapy for CBS (2020)2020 · DOI 10.1016/j.parkreldis.2020.07.012Open reference}2^{4Symptomatic therapy for CBS (2020)2020 · DOI 10.1016/j.parkreldis.2020.07.012Open reference}3. Physical activity triggers BDNF expression through multiple pathways:

• Muscle-to-brain signaling: Exercise induces skeletal muscle expression of FNDC5 (irisin precursor), which is cleaved to irisin and crosses the blood-brain barrier to stimulate BDNF production in hippocampal neurons

• PGC-1α pathway: Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) in muscle cells activates the FNDC5 gene, creating a direct link between aerobic fitness and brain health

• VEGF-mediated angiogenesis: Exercise increases vascular endothelial growth factor (VEGF), promoting cerebral angiogenesis that supports neurotrophic signaling

In CBS/PSP patients, BDNF levels are typically reduced due to tau pathology affecting cortical and hippocampal regions. Exercise interventions can partially restore BDNF signaling, with studies showing 15-30% increases in serum BDNF following 12-week aerobic programs.

Other Neurotrophic Factors

Exercise also promotes additional neurotrophic molecules:

Neuroplasticity Mechanisms in CBS/PSP

Synaptic Plasticity

Tau pathology in CBS/PSP directly impairs synaptic function through:

• LTP disruption: Tau oligomers interfere with NMDA receptor signaling, reducing long-term potentiation

• Dendritic spine loss: Hyperphosphorylated tau destabilizes actin cytoskeleton in dendritic spines

• Network hypoactivity: Tau-induced hyperexcitability followed by depression disrupts cortical circuits

Exercise counteracts these mechanisms by:

1. Enhancing AMPA receptor trafficking to strengthen synaptic transmission

2. Promoting spine formation through BDNF-TrkB signaling

3. Normalizing network excitability through GABAergic modulation

Structural Plasticity

Exercise induces measurable structural changes in CBS/PSP:

• Hippocampal volume: Moderate preservation (2-5% less atrophy) in exercise groups

• White matter integrity: Reduced fractional anisotropy decline in frontostriatal pathways

• Cortical thickness: Less pronounced thinning in motor and premotor regions

Circuit-Level Plasticity

The cortico-basal ganglia-thalamocortical circuits affected in CBS/PSP can be partially restored through:

• Task-specific training targeting affected circuits

• Dual-task paradigms to improve automaticity

• Intensive, distributed practice to promote motor learning

Exercise Intensity Thresholds

Aerobic Exercise

Evidence supports a dose-response relationship for neuroprotective effects:

For CBS/PSP patients, moderate intensity (60-70% HRmax) provides the optimal balance between neuroplasticity benefits and safety.

Minimum Effective Dose

Research suggests:

• Frequency: 3-5 sessions per week required for sustained BDNF elevation

• Duration: 30-45 minutes per session; longer sessions show diminishing returns

• Volume: 150 minutes/week moderate activity is the minimum threshold for neurocognitive benefit

Safety Considerations

CBS/PSP-specific precautions:

1. Fall risk management: Avoid high-intensity interval training that increases postural instability

2. Autonomic dysfunction: PSP patients may have impaired heart rate response; use perceived exertion scales

3. Apraxia management: Cortical stimulation tasks should be supervised to prevent self-injury

4. Fatigue management: Post-exercise fatigue can persist 24-48 hours; allow adequate recovery

Tailored Exercise Protocols for CBS/PSP

Protocol 1: Aerobic Baseline Maintenance

Purpose: Preserve cardiovascular fitness and baseline BDNF levels

• Frequency: 3 days/week

• Duration: 30 minutes

• Intensity: 60-65% HRmax (moderate, RPE 12-13)

• Modality: Stationary cycling or recumbent stepper

• Progression: Increase duration to 45 minutes over 8 weeks, then intensity to 70%

Protocol 2: Dual-Task Training

Purpose: Improve automaticity of movement to reduce cognitive burden

• Frequency: 2 days/week

• Duration: 20-30 minutes

• Components:

  • Walking while naming items (category fluency)

  • Stepping while counting backward from 100 by 7s

  • Balance tasks while solving simple arithmetic

• Progression: Increase task complexity while maintaining accuracy >80%

Protocol 3: Intensive Motor Learning

Purpose: Promote circuit-specific plasticity in affected motor pathways

• Frequency: 4-5 days/week

• Duration: 45-60 minutes

• Components:

  • Task-specific training (reaching, grasping, walking)

  • Constraint-induced movement principles (use affected limb)

  • Errorless learning for apraxic movements

• Progression: Decrease verbal cues over time to promote internal cueing

Protocol 4: Combined Aerobic-Cognitive Training

Purpose: Maximize BDNF and neuroplasticity through simultaneous cognitive challenge

• Frequency: 3 days/week

• Duration: 40 minutes

• Components:

  • 20 min aerobic (65% HRmax) + cognitive task

  • Interleaved 2-min cognitively demanding segments

  • Tasks: virtual reality navigation, dance-based learning

• Evidence: Combined training shows 2x BDNF response vs. either alone

Monitoring and Progression

Clinical Markers

Track these indicators to adjust exercise prescriptions:

1. Serum BDNF: Check at baseline, 12 weeks; target 20% increase

2. 6-Minute Walk Test: Monitor functional capacity; maintain >80% of baseline

3. Timed Up and Go: Track fall risk; any increase >20% signals overtraining

4. MoCA or RBANS: Cognitive function should stabilize or improve

Adjustment Guidelines

Integration with Other Therapies

Exercise synergizes with several CBS/PSP interventions:

• Physical therapy: Formal PT provides structured progression and safety monitoring

• Occupational therapy: Task-specific training for activities of daily living

• Speech therapy: Respiratory exercise for bulbar function

• Pharmacology: BDNF expression enhanced by amantadine; consider timing

Evidence Summary

Exercise physiology and neuroplasticity interventions in CBS/PSP are supported by:

1. Level A evidence: Moderate-intensity aerobic exercise improves global cognition in MCI and early dementia

2. Level B evidence: Dual-task training reduces fall frequency in parkinsonian syndromes

3. Level C evidence: Task-specific motor training improves affected limb function in CBS

4. Expert consensus: Multicomponent exercise programs are recommended for CBS/PSP management

CBS/PSP Cross-Link Hub

High-Priority Navigation

• Progressive Supranuclear Palsy

• Corticobasal Syndrome

• Corticobasal Degeneration

• 4R Tauopathy Mechanism

• Cortisol-Tau Pathway

• Gut-Brain Axis in Tauopathy

• Imaging Biomarkers for CBS/PSP

• Tau PET in CBS/PSP

• MRI Atrophy Patterns in CBS/PSP

• DTI White Matter Changes in CBS/PSP

• CBS/PSP Daily Action Plan

• CBS/PSP Rehabilitation Guide

• CBS/PSP Clinical Trials Guide

• Cognitive Reserve Strategies for CBS/PSP

• Exercise and Physical Activity for CBS/PSP

• Protective Strategies for CBS/PSP

• Melatonin for Tauopathy

• Low-Dose Lithium for Tauopathy

• Rapamycin for Tauopathy

• Senolytics for Neurodegeneration

• TUDCA/UDCA for Neurodegeneration

• Spermidine for Neurodegeneration

• Photobiomodulation for Neurodegeneration

• Urolithin A for Neurodegeneration

• Deferiprone for Neurodegeneration

• Ambroxol for Neurodegeneration

• Omega-3 Fatty Acids for Neurodegeneration

• Coenzyme Q10 for Neurodegeneration

• Alpha-Lipoic Acid for Neurodegeneration

• NAD+ Precursors for Neurodegeneration

• Mitochondrial Support Strategies for CBS/PSP

• Autophagy Enhancement for Tauopathy

• Sodium Channel Modulation for CBS/PSP

• Calcium Channel Modulation for CBS/PSP

• Section 182: Microbiome Metabolomics and SCFA Therapy

• Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

• Section 204: Advanced Proteostasis and Protein Quality Control in CBS/PSP

External Links

• PubMed — Biomedical literature database

• ClinicalTrials.gov — Clinical trial registry

See Also

• CBS/PSP Daily Action Plan

• CBS/PSP Rehabilitation Guide

• CBS/PSP Clinical Trials Guide

• 4R Tauopathy Pathway

• Progressive Supranuclear Palsy

• Corticobasal Syndrome

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

• Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation — 0.73 · Target: BDNF

• Vagal Afferent Microbial Signal Modulation — 0.71 · Target: GLP1R, BDNF

• Vocal Cord Neuroplasticity Stimulation — 0.48 · Target: CHR2/BDNF

• Nutrient-Sensing Epigenetic Circuit Reactivation — 0.79 · Target: SIRT1

• APOE-Dependent Autophagy Restoration — 0.73 · Target: MTOR

• TFEB-PGC1α Mitochondrial-Lysosomal Decoupling — 0.52 · Target: TFEB

• The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction — 0.52 · Target: TFEB

Related Analyses:

• 4R-tau strain-specific spreading patterns in PSP vs CBD 🔄

• Circuit-level neural dynamics in neurodegeneration 🔄

• Digital biomarkers and AI-driven early detection of neurodegeneration 🔄

• What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi 🔄

• Metabolic reprogramming in neurodegenerative disease 🔄